Liraglutide Attenuates Nonalcoholic Fatty Liver Disease through Adjusting Lipid Metabolism via SHP1/AMPK Signaling Pathway

Liraglutide Attenuates Nonalcoholic Fatty Liver Disease through Adjusting Lipid Metabolism via SHP1/AMPK Signaling Pathway

A glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide (LR) had been experimentally and clinically shown to ameliorate nonalcoholic fatty liver disease (NAFLD). This study aimed to investigate the beneficial effect of LR on NAFLD in vivo and in vitro and its underlying molecular mechanism. T...

Full description

Saved in:
Bibliographic Details
Main Authors: Peng Yu, Xi Xu, Jing Zhang, Xuan Xia, Fen Xu, Jianping Weng, Xiaoyang Lai, Yunfeng Shen
Format: Article
Language:English
Published: Wiley 2019-01-01
Series:International Journal of Endocrinology
Online Access:http://dx.doi.org/10.1155/2019/1567095
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items